Exelixis | Beneficio Operativo



Operating Profit Cambio Fecha
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Bayer EUR 3.53B 7.35B 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Cytokinetics USD -139040000 1.76M 2024-12
Eisai JPY 27.56B 13.14B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Exelixis USD 163.21M 27.13M 2025-01
Genmab DKK 2.19B 89M 2024-12
Glaxosmithkline GBP 702M 513M 2024-12
Incyte USD 301.51M 155.43M 2024-12
Ionis Pharmaceuticals USD -110823000 37.83M 2024-12
MacroGenics USD 54.19M 112.37M 2024-09
Merck USD 4.3B 369M 2024-12
Moderna USD -1246000000 1.18B 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Pfizer USD -409000000 5.57B 2024-12
Sanofi EUR 3.64B 1.35B 2024-09
Takeda JPY 66.94B 117.3B 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Xencor USD 4.05M 66.33M 2024-12



Exelixis Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.